Your browser doesn't support javascript.
loading
Tumor suppressor mediated ubiquitylation of hnRNPK is a barrier to oncogenic translation.
Mucha, Bartosz; Qie, Shuo; Bajpai, Sagar; Tarallo, Vincenzo; Diehl, J Nathaniel; Tedeschi, Frank; Zhou, Gao; Gao, Zhaofeng; Flashner, Samuel; Klein-Szanto, Andres J; Hibshoosh, Hanina; Masataka, Shimonosono; Chajewski, Olga S; Majsterek, Ireneusz; Pytel, Dariusz; Hatzoglou, Maria; Der, Channing J; Nakagawa, Hiroshi; Bass, Adam J; Wong, Kwok-Kin; Fuchs, Serge Y; Rustgi, Anil K; Jankowsky, Eckhard; Diehl, J Alan.
Afiliação
  • Mucha B; Department of Biochemistry, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH, 44106, USA.
  • Qie S; Department of Biochemistry, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH, 44106, USA.
  • Bajpai S; Department of Biochemistry, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH, 44106, USA.
  • Tarallo V; Department of Biochemistry, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH, 44106, USA.
  • Diehl JN; Curriculum in Genetics and Molecular Biology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Tedeschi F; Department of Biochemistry, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH, 44106, USA.
  • Zhou G; Center for RNA Science and Therapeutics, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH, 44106, USA.
  • Gao Z; Center for RNA Science and Therapeutics, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH, 44106, USA.
  • Flashner S; Department of Genetics and Genome Sciences, School of Medicine, Case Western Reserve University, Cleveland, OH, 44016, USA.
  • Klein-Szanto AJ; Division of Hematology-Oncology, Department of Medicine, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY, 10032, USA.
  • Hibshoosh H; Histopathology Facility, Fox Chase Cancer Center, Philadelphia, PA, 19111, USA.
  • Masataka S; Division of Hematology-Oncology, Department of Medicine, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY, 10032, USA.
  • Chajewski OS; Division of Hematology-Oncology, Department of Medicine, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY, 10032, USA.
  • Majsterek I; Department of Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston, SC, 29425, USA.
  • Pytel D; Department of Clinical Chemistry and Biochemistry, Medical University of Lodz, 60 Narutowicza St. 90-136, Lodz, Poland.
  • Hatzoglou M; Department of Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston, SC, 29425, USA.
  • Der CJ; Department of Clinical Chemistry and Biochemistry, Medical University of Lodz, 60 Narutowicza St. 90-136, Lodz, Poland.
  • Nakagawa H; Department of Genetics and Genome Sciences, School of Medicine, Case Western Reserve University, Cleveland, OH, 44016, USA.
  • Bass AJ; Curriculum in Genetics and Molecular Biology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Wong KK; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.
  • Fuchs SY; Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.
  • Rustgi AK; Division of Digestive and Liver Diseases, Department of Medicine, Herbert Irving Comprehensive Cancer Research Center, Columbia University Irving Medical Center, New York, NY, 10032, USA.
  • Jankowsky E; Division of Hematology-Oncology, Department of Medicine, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY, 10032, USA.
  • Diehl JA; Division of Hematology and Medical Oncology, Perlmutter Cancer Center, New York University, New York, NY, 10016, USA.
Nat Commun ; 13(1): 6614, 2022 11 03.
Article em En | MEDLINE | ID: mdl-36329064
ABSTRACT
Heterogeneous Nuclear Ribonucleoprotein K (hnRNPK) is a multifunctional RNA binding protein (RBP) localized in the nucleus and the cytoplasm. Abnormal cytoplasmic enrichment observed in solid tumors often correlates with poor clinical outcome. The mechanism of cytoplasmic redistribution and ensuing functional role of cytoplasmic hnRNPK remain unclear. Here we demonstrate that the SCFFbxo4 E3 ubiquitin ligase restricts the pro-oncogenic activity of hnRNPK via K63 linked polyubiquitylation, thus limiting its ability to bind target mRNA. We identify SCFFbxo4-hnRNPK responsive mRNAs whose products regulate cellular processes including proliferation, migration, and invasion. Loss of SCFFbxo4 leads to enhanced cell invasion, migration, and tumor metastasis. C-Myc was identified as one target of SCFFbxo4-hnRNPK. Fbxo4 loss triggers hnRNPK-dependent increase in c-Myc translation, thereby contributing to tumorigenesis. Increased c-Myc positions SCFFbxo4-hnRNPK dysregulated cancers for potential therapeutic interventions that target c-Myc-dependence. This work demonstrates an essential role for limiting cytoplasmic hnRNPK function in order to maintain translational and cellular homeostasis.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Ribonucleoproteínas Nucleares Heterogêneas Grupo K / Carcinogênese Limite: Humans Idioma: En Revista: Nat Commun Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Ribonucleoproteínas Nucleares Heterogêneas Grupo K / Carcinogênese Limite: Humans Idioma: En Revista: Nat Commun Ano de publicação: 2022 Tipo de documento: Article